tiprankstipranks
Allogene Therapeutics Enhances Leadership and Affirms Shareholder Decisions
Company Announcements

Allogene Therapeutics Enhances Leadership and Affirms Shareholder Decisions

Don't Miss our Black Friday Offers:

Allogene Therapeutics (ALLO) has issued an announcement.

Allogene Therapeutics, Inc. has appointed Annie Yoshiyama as its new principal accounting officer, bringing with her extensive financial expertise from previous roles at AN2 Therapeutics, Tricida, and Dolby Laboratories. In parallel, the company’s 2024 Annual Meeting witnessed the election of four Class III Directors, approval of executive compensation, and ratification of Ernst & Young LLP as its independent auditor for the year, with significant shareholder participation and support for these agendas.

See more data about ALLO stock on TipRanks’ Stock Analysis page.

Related Articles
TheFlyAllogene Therapeutics presents data for ALLO-329 in autoimmune disease
TheFlyAllogene Therapeutics price target lowered to $9 from $11 at Piper Sandler
TipRanks Auto-Generated NewsdeskAllogene Therapeutics Advances CAR T Therapies
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App